Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RIVAC regimen

A regimen consisting of rituximab, ifosfamide, cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	R-IVAC regimen rituximab + ifosfamide + cytarabine + etoposide rituximab-ifosfamide-cytarabine-etoposide rituximab/ifosfamide/cytarabine/etoposide rituximab/ifosphamide/VP-16/ARA-C
Abbreviation:	R-IVAC RIVAC

RIVAC regimen

Search NCI's Drug Dictionary